Australia markets open in 6 hours 48 minutes
  • ALL ORDS

    7,339.30
    -52.40 (-0.71%)
     
  • AUD/USD

    0.7089
    +0.0000 (+0.00%)
     
  • ASX 200

    7,105.90
    -49.30 (-0.69%)
     
  • OIL

    114.33
    +4.00 (+3.63%)
     
  • GOLD

    1,846.90
    +0.60 (+0.03%)
     
  • BTC-AUD

    41,666.41
    -302.77 (-0.72%)
     
  • CMC Crypto 200

    648.46
    -12.68 (-1.92%)
     

One Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) insider upped their stake by 148% in the previous year

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Viewing insider transactions for Cerevel Therapeutics Holdings, Inc.'s (NASDAQ:CERE ) over the last year, we see that insiders were net buyers. This means that a larger number of shares were purchased by insiders in relation to shares sold.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for Cerevel Therapeutics Holdings

Cerevel Therapeutics Holdings Insider Transactions Over The Last Year

The Independent Director Gabrielle Greene-Sulzberger made the biggest insider purchase in the last 12 months. That single transaction was for US$275k worth of shares at a price of US$13.06 each. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$31.91. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

Cerevel Therapeutics Holdings is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership of Cerevel Therapeutics Holdings

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data indicates that Cerevel Therapeutics Holdings insiders own about US$5.5m worth of shares (which is 0.1% of the company). We do generally prefer see higher levels of insider ownership.

What Might The Insider Transactions At Cerevel Therapeutics Holdings Tell Us?

There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Cerevel Therapeutics Holdings stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Cerevel Therapeutics Holdings. To that end, you should learn about the 5 warning signs we've spotted with Cerevel Therapeutics Holdings (including 2 which shouldn't be ignored).

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting